May 8, 2024 - 7:10pm

→ Cambridge journal ditches Anglo-Saxon name

Cambridge University Press is launching a new academic journal covering the Middle Ages, called Early Medieval England and its Neighbours (EMEN). This afternoon’s announcement should have been a boon to Æthelstan nerds, but Cambridge is instead receiving flak for once again kowtowing to political correctness.

That’s because EMEN is in fact a relaunch of the publication Anglo-Saxon England. The University of Cambridge has had previous issues with Alfred the Great & co. Last year it was reported that the department responsible for early medieval history was teaching students that the Anglo-Saxons were not a distinct ethnic group, in an effort to tackle “myths of nationalism” and make the university curriculum more “anti-racist”.

Historians are now less than pleased with the CUP journal’s name change, with noted podcaster Dominic Sandbrook calling the individuals behind the decision “total drips” and accusing them of not having “the courage to say no to a handful of mad Americans”. First the Normans, now the American conquest


→ Most college kids don’t care about Israel-Palestine

Students tend to get a bad rap for, as Terry Eagleton puts it, “prating of revolution while too smashed on dope to erect a tent pole, let alone a barricade”. But is it really fair to be blaming all students for the actions of a small and vocal minority?

Credit: Axios

The frat boy reaction was one thing, but new research from Axios has confirmed that only around 8% of college students have participated in either side of the protests. Based on a survey of 1,250 university students, it also found that respondents ranked the Middle East conflict as the least important issue facing them out of nine offered. Maybe the kids are alright


→ Sceptics celebrate withdrawal of AstraZeneca Covid vaccine

Vaccine sceptics have been enjoying a victory lap today after AstraZeneca pulled its Covid-19 vaccine. Citing weak demand and the rise of other vaccines, the British-Swedish drugmaker announced that there would be a worldwide withdrawal.

But is weak demand really to blame? As some onlookers have pointed out, AstraZeneca admitted months ago that the drug could cause very rare, but life-threatening, injuries. It could well be that “weak demand” is a convenient foil for this rather more troubling revelation. No comment yet from the brain-wormed RFK Jr